UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Position in Omnicell, Inc. (NASDAQ:OMCL)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 22.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 119,181 shares of the company's stock after acquiring an additional 21,847 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.26% of Omnicell worth $5,306,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Smartleaf Asset Management LLC lifted its stake in Omnicell by 51.5% during the fourth quarter. Smartleaf Asset Management LLC now owns 803 shares of the company's stock worth $35,000 after purchasing an additional 273 shares during the last quarter. Johnson Financial Group Inc. acquired a new stake in Omnicell in the fourth quarter valued at about $37,000. Van ECK Associates Corp grew its position in Omnicell by 47.0% in the fourth quarter. Van ECK Associates Corp now owns 985 shares of the company's stock valued at $44,000 after acquiring an additional 315 shares during the last quarter. Headlands Technologies LLC acquired a new position in Omnicell during the fourth quarter worth about $53,000. Finally, First Horizon Advisors Inc. lifted its holdings in shares of Omnicell by 36.3% in the fourth quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company's stock worth $59,000 after acquiring an additional 355 shares during the last quarter. 97.70% of the stock is owned by institutional investors and hedge funds.

Omnicell Trading Down 1.5%

Shares of OMCL stock traded down $0.48 during mid-day trading on Thursday, reaching $30.81. The stock had a trading volume of 183,110 shares, compared to its average volume of 569,286. The company has a current ratio of 1.37, a quick ratio of 1.22 and a debt-to-equity ratio of 0.13. Omnicell, Inc. has a 52-week low of $22.66 and a 52-week high of $55.75. The firm has a market capitalization of $1.44 billion, a PE ratio of 114.54, a price-to-earnings-growth ratio of 7.53 and a beta of 0.78. The stock's 50-day moving average price is $30.17 and its two-hundred day moving average price is $37.76.

Omnicell (NASDAQ:OMCL - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported $0.26 EPS for the quarter, topping the consensus estimate of $0.16 by $0.10. The business had revenue of $269.67 million for the quarter, compared to analyst estimates of $260.18 million. Omnicell had a net margin of 1.13% and a return on equity of 3.82%. Omnicell's quarterly revenue was up 9.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.03 earnings per share. Equities analysts expect that Omnicell, Inc. will post 1.09 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the stock. Bank of America lifted their target price on shares of Omnicell from $30.00 to $34.00 and gave the stock a "neutral" rating in a research report on Friday, May 23rd. Wells Fargo & Company reaffirmed an "overweight" rating and set a $37.00 target price (up from $35.00) on shares of Omnicell in a research report on Friday, May 23rd. JPMorgan Chase & Co. lowered their price objective on Omnicell from $44.00 to $36.00 and set a "neutral" rating for the company in a research report on Thursday, March 20th. Wall Street Zen upgraded shares of Omnicell from a "hold" rating to a "buy" rating in a report on Tuesday, May 20th. Finally, Benchmark dropped their price target on Omnicell from $62.00 to $40.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $44.83.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.